Pablo Vivas to Neovascularization, Pathologic
This is a "connection" page, showing publications Pablo Vivas has written about Neovascularization, Pathologic.
Connection Strength
0.302
-
Villarreal-Garc?a V, Estupi?an-Jim?nez JR, Gonzalez-Villasana V, Vivas-Mej?a PE, Flores-Col?n M, Ancira-Moreno IE, Zapata-Mor?n PA, Altamirano-Torres C, V?zquez-Guillen JM, Rodr?guez-Padilla C, Bayraktar R, Rashed MH, Ivan C, Lopez-Berestein G, Res?ndez-P?rez D. Inhibition of microRNA-660-5p decreases breast cancer progression through direct targeting of TMEM41B. Hereditas. 2024 Dec 21; 161(1):53.
Score: 0.210
-
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.
Score: 0.074
-
Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 2009 Oct 22; 4(10):e7502.
Score: 0.018